LncRNA RP11-89 Facilitates Tumorigenesis and Ferroptosis Resistance Through PROM2-activated Iron Export by Sponging Mir-129-5p in Bladder Cancer.

Wenjie Luo,Jun Wang,Wenhao Xu,Chunguang Ma,Fangning Wan,Yongqiang Huang,Mengfei Yao,Hailiang Zhang,Yuanyuan Qu,Dingwei Ye,Yiping Zhu
DOI: https://doi.org/10.1038/s41419-021-04296-1
2021-01-01
Cell Death and Disease
Abstract:Long non-coding RNAs (lncRNAs) act as important regulators of tumorigenesis and development in bladder cancer. However, the underlying molecular mechanisms remain elusive. We previously identified a novel lncRNA signature related to immunity and progression in bladder cancer. Here we further explored the function of RP11-89, a lncRNA discovered in the previous signature. Loss- and gain-of function experiments were performed using CCK-8 assay, flow cytometry, Transwell assays, scratch tests and subcutaneous nude mouse models. High-throughput RNA sequencing was conducted to identify dysregulated genes in bladder cancer cells with RP11-89 knockdown or overexpression. Regulation of RP11-89 on miR-129-5p and PROM2 was explored through luciferase reporter assay, RIP assay and RNA pull-down assay. RP11-89 promoted cell proliferation, migration and tumorigenesis and inhibited cell cycle arrest via the miR-129-5p/PROM2 axis. We found that RP11-89 "sponges" miR-129-5p and upregulates PROM2. Elevated PROM2 in cells was associated with attenuated ferroptosis through iron export, formation of multivesicular bodies and less mitochondrial abnormalities. We demonstrated that RP11-89 is a novel tumorigenic regulator that inhibits ferroptosis via PROM2-activated iron export. RP11-89 may serve as a potential biomarker for targeted therapy in bladder cancer.
What problem does this paper attempt to address?